Capitalizzazione – Sanità
Settore sanitario per azienda (USD) gen 2000 - set 2026
In sintesi
Nel set 2026, Eli Lilly al primo posto con 1,02 Bln USD, davanti a Johnson & Johnson (663,28 Mld USD).
Eli Lilly da solo: 22,7% del totale set 2026.
Dal set 2016, maggiore crescita per Eli Lilly: 1574,7%.
Classifiche Complete
Set di dati completo - set 2026
| Posizione | Azienda | Valore | M/M | Quota % | Δ Posizione |
|---|---|---|---|---|---|
| 1 | ![](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="40" height="40" viewBox="0 0 40 40"><circle cx="20" cy="20" r="18" fill="%23334155" stroke="%23475569" stroke-width="1.5"/><text x="20" y="21" text-anchor="middle" dominant-baseline="central" fill="white" font-size="11" font-family="ui-monospace,monospace" font-weight="600">LLY</text></svg>) Eli LillyLLY | 1 Bln USD | -0,6% | 22,7% | — |
| 2 | ![](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="40" height="40" viewBox="0 0 40 40"><circle cx="20" cy="20" r="18" fill="%23334155" stroke="%23475569" stroke-width="1.5"/><text x="20" y="21" text-anchor="middle" dominant-baseline="central" fill="white" font-size="11" font-family="ui-monospace,monospace" font-weight="600">JNJ</text></svg>) Johnson & JohnsonJNJ | 663,3 Mld USD | +3,5% | 14,7% | — |
| 3 | ![](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="40" height="40" viewBox="0 0 40 40"><circle cx="20" cy="20" r="18" fill="%23334155" stroke="%23475569" stroke-width="1.5"/><text x="20" y="21" text-anchor="middle" dominant-baseline="central" fill="white" font-size="11" font-family="ui-monospace,monospace" font-weight="600">ABBV</text></svg>) AbbVieABBV | 453,2 Mld USD | 0,0% | 10,1% | — |
| 4 | ![](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="40" height="40" viewBox="0 0 40 40"><circle cx="20" cy="20" r="18" fill="%23334155" stroke="%23475569" stroke-width="1.5"/><text x="20" y="21" text-anchor="middle" dominant-baseline="central" fill="white" font-size="11" font-family="ui-monospace,monospace" font-weight="600">MRK</text></svg>) MerckMRK | 370,9 Mld USD | +1,7% | 8,2% | — |
| 5 | ![](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="40" height="40" viewBox="0 0 40 40"><circle cx="20" cy="20" r="18" fill="%23334155" stroke="%23475569" stroke-width="1.5"/><text x="20" y="21" text-anchor="middle" dominant-baseline="central" fill="white" font-size="11" font-family="ui-monospace,monospace" font-weight="600">UNH</text></svg>) UnitedHealth GroupUNH | 356,5 Mld USD | +2,0% | 7,9% | — |
| 6 | ![](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="40" height="40" viewBox="0 0 40 40"><circle cx="20" cy="20" r="18" fill="%23334155" stroke="%23475569" stroke-width="1.5"/><text x="20" y="21" text-anchor="middle" dominant-baseline="central" fill="white" font-size="11" font-family="ui-monospace,monospace" font-weight="600">NVS</text></svg>) NovartisNVS | 304,1 Mld USD | +5,2% | 6,7% | — |
| 7 | ![](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="40" height="40" viewBox="0 0 40 40"><circle cx="20" cy="20" r="18" fill="%23334155" stroke="%23475569" stroke-width="1.5"/><text x="20" y="21" text-anchor="middle" dominant-baseline="central" fill="white" font-size="11" font-family="ui-monospace,monospace" font-weight="600">AZN</text></svg>) AstraZenecaAZN | 252,3 Mld USD | +0,4% | 5,6% | — |
| 8 | ![](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="40" height="40" viewBox="0 0 40 40"><circle cx="20" cy="20" r="18" fill="%23334155" stroke="%23475569" stroke-width="1.5"/><text x="20" y="21" text-anchor="middle" dominant-baseline="central" fill="white" font-size="11" font-family="ui-monospace,monospace" font-weight="600">TMO</text></svg>) Thermo Fisher ScientificTMO | 226,9 Mld USD | -0,5% | 5,0% | — |
| 9 | ![](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="40" height="40" viewBox="0 0 40 40"><circle cx="20" cy="20" r="18" fill="%23334155" stroke="%23475569" stroke-width="1.5"/><text x="20" y="21" text-anchor="middle" dominant-baseline="central" fill="white" font-size="11" font-family="ui-monospace,monospace" font-weight="600">NVO</text></svg>) Novo NordiskNVO | 206 Mld USD | +2,8% | 4,6% | — |
| 10 | ![](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="40" height="40" viewBox="0 0 40 40"><circle cx="20" cy="20" r="18" fill="%23334155" stroke="%23475569" stroke-width="1.5"/><text x="20" y="21" text-anchor="middle" dominant-baseline="central" fill="white" font-size="11" font-family="ui-monospace,monospace" font-weight="600">PFE</text></svg>) PfizerPFE | 162,2 Mld USD | 0,0% | 3,6% | — |
| 11 | ![](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="40" height="40" viewBox="0 0 40 40"><circle cx="20" cy="20" r="18" fill="%23334155" stroke="%23475569" stroke-width="1.5"/><text x="20" y="21" text-anchor="middle" dominant-baseline="central" fill="white" font-size="11" font-family="ui-monospace,monospace" font-weight="600">DHR</text></svg>) DanaherDHR | 146 Mld USD | -2,8% | 3,2% | — |
| 12 | ![](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="40" height="40" viewBox="0 0 40 40"><circle cx="20" cy="20" r="18" fill="%23334155" stroke="%23475569" stroke-width="1.5"/><text x="20" y="21" text-anchor="middle" dominant-baseline="central" fill="white" font-size="11" font-family="ui-monospace,monospace" font-weight="600">BMY</text></svg>) Bristol-Myers SquibbBMY | 136,5 Mld USD | 0,0% | 3,0% | — |
| 13 | ![](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="40" height="40" viewBox="0 0 40 40"><circle cx="20" cy="20" r="18" fill="%23334155" stroke="%23475569" stroke-width="1.5"/><text x="20" y="21" text-anchor="middle" dominant-baseline="central" fill="white" font-size="11" font-family="ui-monospace,monospace" font-weight="600">SNY</text></svg>) SanofiSNY | 106 Mld USD | -0,3% | 2,4% | — |
| 14 | ![](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="40" height="40" viewBox="0 0 40 40"><circle cx="20" cy="20" r="18" fill="%23334155" stroke="%23475569" stroke-width="1.5"/><text x="20" y="21" text-anchor="middle" dominant-baseline="central" fill="white" font-size="11" font-family="ui-monospace,monospace" font-weight="600">GSK</text></svg>) GSKGSK | 99,9 Mld USD | -0,7% | 2,2% | — |
Fonte dei dati e licenza
Rilasciato sotto licenza Yahoo Terms of Service.
I dati vengono recuperati dalla fonte originale e formattati da Data Race.
Set di Dati Correlati
Economia
Classifica per capitalizzazione di mercato
Capitalizzazione di mercato per azienda
gen 2000-set 2026 130 Azienda
Economia
Capitalizzazione – Tecnologia
Settore tecnologico per azienda
gen 2000-set 2026 16 Azienda
Economia
Capitalizzazione – Semiconduttori
Settore semiconduttori per azienda
gen 2000-set 2026 15 Azienda
Economia
Capitalizzazione – Finanza
Settore finanziario per azienda
gen 2000-set 2026 15 Azienda
Economia
Capitalizzazione – Energia
Settore energetico per azienda
gen 2000-set 2026 14 Azienda
Economia
Capitalizzazione – Beni di consumo
Settore dei beni di consumo per azienda
gen 2000-set 2026 14 Azienda